Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05310071 · ClinicalTrials.gov registry record · Phase 3
A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease
A Phase 3 study, sponsored by Biogen.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,027
- Enrollment target
NCT05310071 is a Phase 3 study that was terminated before completion, run by Biogen. The registered enrollment target is 1,027 participants.
The verdict
NCT05310071, a Phase 3 study, was terminated before completion, sponsored by Biogen.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,027 participants
- Enrollment target
Study Summary
The primary objective of this study is to verify the clinical benefit of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) score as compared with placebo in participants with early Alzheimer's disease.
Interventions
- DRUG Placebo
- DRUG Aducanumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,027 participants |
| Start Date | 2022-06-02 |
| Est. Completion | 2024-08-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05310071
The ClinicalTrials.gov registry entry for NCT05310071 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 1,027 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05310071 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05310071 about?
NCT05310071 is a clinical study titled "A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease". The primary objective of this study is to verify the clinical benefit of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) score as compared with placebo in participants with early Alzheimer's...
What is the current status of trial NCT05310071?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,027 participants. The study started on 2022-06-02. Estimated completion is 2024-08-12.
What interventions are being tested in trial NCT05310071?
The interventions under investigation include: Placebo (DRUG), Aducanumab (DRUG).
Who is sponsoring clinical trial NCT05310071?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.